| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We performed experiments on animal model and clinical study to aim to make visible the microglia activation by neuroimaging. PK11195 is antagonist of peripheral benzodiazepine receptor (PBR) that migrate to cell membrane depending on the microglia activation in response to spinal cord dysfunction.
In the animal model, PBR positive cells were colocalized with CD11b and iba-1. Most of PBR-positive cells were not merged with GFP-positive cells. In autoradiography, accumulation of PK11195 was identified after injury. In the clinical study, no uptake was seen in the healthy volunteer and the uptake was seen only in patients within one year after the neuropathic pain onset. Our results suggest that PBR is mainly located in activated microglia, and [11C]-PK11195 PET/MRI imaging is available to investigate whether microglial activation is evident in for the patients with neuropathic pain.
|
